Results 131 to 140 of about 52,295 (246)

Causal Effects of Renin-Angiotensin-Aldosterone System Inhibition on Renal Function in Patients With Chronic Kidney Disease: A Quasi-Experimental Study. [PDF]

Clin Transl Sci
Oh TR, Park J, Choi HS, Rhee H, Kang G.
europepmc   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

The Renin-Angiotensin-Aldosterone System in Cardiac Surgery and Angiotensin II Therapy for Vasoplegia. [PDF]

Anesth Analg
Zarbock A, Vincent JL, De Backer D, Bellomo R, Legrand M, Khanna AK, Ostermann M, Kotfis K, Filippo A, Wieruszewski PM, Leone M, Girardis M, Ferrer R, Kotani Y, Pickkers P, De Pascale G, Tissieres P, Landoni G.   +17 more
europepmc   +1 more source

Molecular Mechanisms of Food Bioactive Constituents in the Management of Obesity and Hypertension: A Critical Review

Phytochemicals in Food and Medicine, Volume 1, Issue 3, September 2026.
Obesity and hypertension co‐exist and share molecular mechanisms in terms of dietary therapy, modulated by food bioactive constituents. ABSTRACT Obesity and hypertension are among the most pressing global public health challenges. They frequently co‐exist, with obesity‐related hypertension accounting for an estimated 75% of the hypertension burden ...
Samuel Oluwasegun Maccarthy, Emmanuel Anyachukwu Irondi, Abdulazeez Olamilekan Elemosho, Emmanuel Oladipo Ajani   +3 more
wiley   +1 more source

Vasopressin and fluid retention after liver resection: Comparison with the renin-angiotensin-aldosterone system by surgical extent and liver function. [PDF]

World J Gastroenterol
Aoki Y, Kawano Y, Ga R, Endo K, Ueda J, Shimizu T, Yoshida H.   +6 more
europepmc   +1 more source

Impaired Renal Base Excretion in Secretin Receptor Knock‐Out Mice During Prolonged Base‐Loading

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT Aim Secretin was recently found to play a pivotal role in the renal adaptation to acute base excess. Here, secretin increases pendrin‐dependent HCO3− secretion from the beta‐intercalated cells in the cortical collecting ducts. Whether secretin and its receptor play a role during prolonged base‐loading remains unknown.
Tobias Jensen, Jesper Frank Andersen, Laura Woidemann Trans, Ida Marie Modvig, Helga Vitzthum, Jens Juul Holst, Bolette Hartman, Samuel L. Svendsen, Mads Vaarby Sørensen, Jens Leipziger, Peder Berg   +10 more
wiley   +1 more source

Effect of renin-angiotensin-aldosterone system inhibitor and statin medication on periodontal status of patients at risk of cardiovascular disease: a systematic review and meta-analysis. [PDF]

Saudi Dent J
Khalilurrahman ZA, Anjani SK, Sulijaya B, Haerani N, Lessang R, Harsas NA, Rahdewati H.   +6 more
europepmc   +1 more source

Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE‐O Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8552-8559, September 2026.
ABSTRACT Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow‐up of 1.81 years. This exploratory mediation analysis evaluates the degree to which changes in measured clinical variables ...
Daniel Raaschou‐Oddershede, Christine R. Schwarz, Tanya Kovalova, Kelley R. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar, Hertzel C. Gerstein   +10 more
wiley   +1 more source

Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection. [PDF]

Biomedicines
Aazar RFM, Arzouni R, Nicolaou PA.
europepmc   +1 more source

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2924-2936, August 2026.
Aim A prior non‐randomized study suggests that potassium supplementation may improve survival among furosemide initiators, and a randomized trial suggests that salt substitutes containing potassium might lower stroke risk. We conducted a retrospective cohort study using health‐care data to confirm or refute these associations among new users of ...
Thanh Phuong Pham Nguyen, Sean Hennessy, Colleen M. Brensinger, Warren B. Bilker, Laura M. Dember, Todd A. Miano, Tat‐Thang Vo, Allison W. Willis, Charles E. Leonard   +8 more
wiley   +1 more source